{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T07:20:35Z","timestamp":1772349635206,"version":"3.50.1"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T00:00:00Z","timestamp":1658188800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The aim of the study was to systematically review evidence on the effectiveness and safety of oral mexiletine administered in monotherapy or in combination with other antiarrhythmic drugs for recurrent ventricular arrhythmia (ventricular tachycardia\/ventricular fibrillation, VT\/VF) in adult patients with structural heart disease (SHD) and implantable cardioverter defibrillators (ICDs). We systematically searched MEDLINE, Embase, and CENTRAL databases from inception to 27 August 2021 for prospective and retrospective studies investigating mexiletine in the target population. The main outcome was the reduction of ICD therapy. The main safety outcome was the presence of any serious adverse events (SAEs) leading to mexiletine discontinuation. Study quality was assessed using the Cochrane risk of bias tool or the Newcastle\u2013Ottawa scale. Four studies comprising 86 mexiletine recipients were included in the review. We also obtained individual data of 50 patients from two studies. Ischaemic cardiomyopathy (ICM) was present in 86% of patients. The quality of included studies was moderate\/low. A narrative review was undertaken as studies varied widely in terms of study population and treatment. Across studies, mexiletine treatment (with or without amiodarone) seemed to consistently reduce the number of ICD therapies especially in a population where catheter ablation (CA) was unsuccessful or contraindicated. In ICM patients deemed eligible for CA, mexiletine seemed to be inferior to CA. Mexiletine was discontinued in 14% of cases, mainly for gastrointestinal or neurological SAE. Mexiletine seems to be an option for the long-term treatment of recurrent VT\/VF in adult patients with SHD, especially ICM, and ICD in whom CA was unsuccessful or not suitable.<\/jats:p>","DOI":"10.1093\/europace\/euac101","type":"journal-article","created":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T08:18:57Z","timestamp":1658218737000},"page":"1504-1511","source":"Crossref","is-referenced-by-count":7,"title":["Mexiletine for recurrent ventricular tachycardia in adult patients with structural heart disease and implantable cardioverter defibrillator: an EHRA systematic review"],"prefix":"10.1093","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1673-7712","authenticated-orcid":false,"given":"Michal Miroslaw","family":"Farkowski","sequence":"first","affiliation":[{"name":"II Department of Heart Arrhythmia, National Institute of Cardiology , Alpejska 42, 04-628 Warsaw , Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6728-2020","authenticated-orcid":false,"given":"Michal","family":"Karlinski","sequence":"additional","affiliation":[{"name":"II Department of Neurology, Institute of Psychiatry and Neurology , Warsaw , Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariusz","family":"Pytkowski","sequence":"additional","affiliation":[{"name":"II Department of Heart Arrhythmia, National Institute of Cardiology , Alpejska 42, 04-628 Warsaw , Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"de Asmundis","sequence":"additional","affiliation":[{"name":"Heart Rhythm Management Centre, Universitair Ziekenhuis Brussel\u2014Vrije Universiteit Brussel , Brussels , Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6829-7491","authenticated-orcid":false,"given":"Michal","family":"Lewandowski","sequence":"additional","affiliation":[{"name":"II Department of Heart Arrhythmia, National Institute of Cardiology , Alpejska 42, 04-628 Warsaw , Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giacomo","family":"Mugnai","sequence":"additional","affiliation":[{"name":"Division of Cardiology, West Vicenza General Hospitals , Arzignano (Vicenza) , Italy"},{"name":"Division of Cardiology, Department of Medicine, University Hospital of Verona , Verona , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2248-3456","authenticated-orcid":false,"given":"Giulio","family":"Conte","sequence":"additional","affiliation":[{"name":"Cardiology Department, Cardiocentro Ticino Institute , Lugano , Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7227-3428","authenticated-orcid":false,"given":"Eloi","family":"Marijon","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Cardiologie, Universit\u00e9 Paris-Descartes, H\u00f4pital Europ\u00e9en Georges Pompidou , Paris , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6864-3999","authenticated-orcid":false,"given":"Ante","family":"Anic","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Clinical Hospital Split , Split , Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1280-7042","authenticated-orcid":false,"given":"Serge","family":"Boveda","sequence":"additional","affiliation":[{"name":"Heart Rhythm Management Centre, Universitair Ziekenhuis Brussel\u2014Vrije Universiteit Brussel , Brussels , Belgium"},{"name":"Heart Rhythm Management Department, Clinique Pasteur , Toulouse , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Providencia","sequence":"additional","affiliation":[{"name":"St Bartholomew\u2019s Hospital, Barts Heart Centre, Barts Health NHS Trust , London , UK"},{"name":"Institute of Health Informatics, University College of London , London , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,7,19]]},"reference":[{"key":"2022101319165094700_euac101-B1","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/j.hrthm.2017.10.036","article-title":"2017 AHA\/ACC\/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society","volume":"15","author":"Al-Khatib","year":"2018","journal-title":"Heart Rhythm"},{"key":"2022101319165094700_euac101-B2","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S1099-5129(03)00078-3","article-title":"Implantable cardioverter defibrillator recipients: quality of life in recipients with and without ICD shock delivery a prospective study","volume":"5","author":"Kamphuis","year":"2003","journal-title":"Europace"},{"key":"2022101319165094700_euac101-B3","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1056\/NEJMoa071098","article-title":"Prognostic importance of defibrillator shocks in patients with heart failure","volume":"359","author":"Poole","year":"2008","journal-title":"N Engl J Med"},{"key":"2022101319165094700_euac101-B4","first-page":"1601","article-title":"2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death","volume":"17","author":"Priori","year":"2015","journal-title":"Europace"},{"key":"2022101319165094700_euac101-B5","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/eurheartj\/eht451","article-title":"Association between myocardial substrate, implantable cardioverter defibrillator shocks and mortality in MADIT-CRT","volume":"35","author":"Sood","year":"2014","journal-title":"Eur Heart J"},{"key":"2022101319165094700_euac101-B6","doi-asserted-by":"crossref","first-page":"e007600","DOI":"10.1161\/CIRCEP.119.007600","article-title":"Antiarrhythmic drugs or catheter ablation in the management of ventricular tachyarrhythmias in patients with implantable cardioverter-defibrillators: a systematic review and meta-analysis of randomized controlled trials","volume":"12","author":"Kheiri","year":"2019","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"2022101319165094700_euac101-B7","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/jce.13431","article-title":"Mexiletine or catheter ablation after amiodarone failure in the VANISH trial","volume":"29","author":"Deyell","year":"2018","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2022101319165094700_euac101-B8","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.5603\/KP.2017.0189","article-title":"Efficacy and tolerability of mexiletine treatment in patients with recurrent ventricular tachyarrhythmias and implantable cardioverter-defibrillator shocks","volume":"75","author":"Sobiech","year":"2017","journal-title":"Kardiol Pol"},{"key":"2022101319165094700_euac101-B9","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1016\/j.hrthm.2020.06.025","article-title":"Bipolar radiofrequency ablation for ventricular tachycardias originating from the interventricular septum: safety and efficacy in a pilot cohort study","volume":"17","author":"Della Bella","year":"2020","journal-title":"Heart Rhythm"},{"key":"2022101319165094700_euac101-B10","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1093\/europace\/euab304","article-title":"Bipolar ablation of therapy-refractory ventricular arrhythmias: application of a dedicated approach","volume":"24","author":"Kany","year":"2022","journal-title":"Europace"},{"key":"2022101319165094700_euac101-B11","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.hrthm.2019.09.016","article-title":"Renal denervation as adjunctive therapy to cardiac sympathetic denervation for ablation refractory ventricular tachycardia","volume":"17","author":"Bradfield","year":"2020","journal-title":"Heart Rhythm"},{"key":"2022101319165094700_euac101-B12","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.phrs.2019.03.020","article-title":"Anti-arrhythmic drug therapy in implantable cardioverter-defibrillator recipients","volume":"143","author":"AlTurki","year":"2019","journal-title":"Pharmacol Res"},{"key":"2022101319165094700_euac101-B13","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/clc.4960130509","article-title":"Mexiletine: pharmacology and therapeutic use","volume":"13","author":"Manolis","year":"1990","journal-title":"Clin Cardiol"},{"key":"2022101319165094700_euac101-B14","doi-asserted-by":"crossref","first-page":"374","DOI":"10.2165\/00003495-199040030-00005","article-title":"A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of arrhythmias","volume":"40","author":"Monk","year":"1990","journal-title":"Drugs"},{"key":"2022101319165094700_euac101-B15","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1093\/europace\/eux373","article-title":"Antiarrhythmic drugs-clinical use and clinical decision making: a consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and International Society of Cardiovascular Pharmacotherapy (ISCP)","volume":"20","author":"Dan","year":"2018","journal-title":"Europace"},{"key":"2022101319165094700_euac101-B16","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"2022101319165094700_euac101-B17","doi-asserted-by":"crossref","first-page":"e0176210","DOI":"10.1371\/journal.pone.0176210","article-title":"Systematic review finds that study data not published in full text articles have unclear impact on meta-analyses results in medical research","volume":"12","author":"Schmucker","year":"2017","journal-title":"PLoS One"},{"key":"2022101319165094700_euac101-B18","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"2022101319165094700_euac101-B19","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1080\/00015385.2021.1926628","article-title":"Mexiletine for ventricular arrhythmias in patients with chronic coronary syndrome: a cohort study","volume":"77","author":"Mugnai","year":"2022","journal-title":"Acta Cardiol"},{"key":"2022101319165094700_euac101-B20","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/jce.12567","article-title":"Catheter ablation for ventricular tachycardia in patients with an implantable cardioverter defibrillator (CALYPSO) pilot trial","volume":"26","author":"Al-Khatib","year":"2015","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2022101319165094700_euac101-B21","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jacep.2015.05.008","article-title":"Mexiletine prevents recurrent Torsades de Pointes in acquired long QT syndrome refractory to conventional measures","volume":"1","author":"Badri","year":"2015","journal-title":"JACC Clin Electrophysiol"},{"key":"2022101319165094700_euac101-B22","doi-asserted-by":"crossref","first-page":"e007280","DOI":"10.1161\/CIRCEP.118.007280","article-title":"Mexiletine shortens the QT interval in patients with potassium channel-mediated type 2 long QT syndrome","volume":"12","author":"Bos","year":"2019","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"2022101319165094700_euac101-B23","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/pace.12250","article-title":"Combination drug therapy for patients with intractable ventricular tachycardia associated with right ventricular cardiomyopathy","volume":"37","author":"Ermakov","year":"2014","journal-title":"Pacing Clin Electrophysiol"},{"key":"2022101319165094700_euac101-B24","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.jacc.2008.10.044","article-title":"Characteristics of recurrent ventricular fibrillation associated with inferolateral early repolarization role of drug therapy","volume":"53","author":"Ha\u00efssaguerre","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2022101319165094700_euac101-B25","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/0002-9149(92)90354-2","article-title":"Effects of chronic amiodarone therapy on defibrillation threshold","volume":"70","author":"Jung","year":"1992","journal-title":"Am J Cardiol"},{"key":"2022101319165094700_euac101-B26","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jacc.2015.12.033","article-title":"Gene-specific therapy with mexiletine reduces arrhythmic events in patients with long QT syndrome type 3","volume":"67","author":"Mazzanti","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2022101319165094700_euac101-B27","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1253\/circj.CJ-15-0213","article-title":"Clinical and electrocardiographic characteristics of electrical storms due to monomorphic ventricular tachycardia refractory to intravenous amiodarone","volume":"79","author":"Murata","year":"2015","journal-title":"Circ J"},{"key":"2022101319165094700_euac101-B28","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jelectrocard.2016.09.005","article-title":"The effects of pure potassium channel blocker nifekalant and sodium channel blocker mexiletine on malignant ventricular tachyarrhythmias","volume":"50","author":"Otuki","year":"2017","journal-title":"J Electrocardiol"},{"key":"2022101319165094700_euac101-B29","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1513614","article-title":"Ventricular tachycardia ablation versus escalation of antiarrhythmic drugs","volume":"375","author":"Sapp","year":"2016","journal-title":"N Engl J Med"},{"key":"2022101319165094700_euac101-B30","doi-asserted-by":"crossref","first-page":"S295","DOI":"10.1016\/j.cjca.2014.07.528","article-title":"Mexiletine use for ventricular tachycardia refractory to standard antiarrhythmic therapy in the ICD era","volume":"30","author":"Padfield","year":"2014","journal-title":"Canadian J Cardiol"},{"key":"2022101319165094700_euac101-B31","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/FJC.0b013e31829651fe","article-title":"Mexiletine as an adjunctive therapy to amiodarone reduces the frequency of ventricular tachyarrhythmia events in patients with an implantable defibrillator","volume":"62","author":"Gao","year":"2013","journal-title":"J Cardiovasc Pharmacol"},{"key":"2022101319165094700_euac101-B32","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0002-9149(80)80015-4","article-title":"Mexiletine therapy in 15 patients with drug-resistant ventricular tachycardia","volume":"45","author":"Heger","year":"1980","journal-title":"Am J Cardiol"},{"key":"2022101319165094700_euac101-B33","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/S0735-1097(84)80133-3","article-title":"International mexiletine and placebo antiarrhythmic coronary trial: I. Report on arrhythmia and other findings. Impact Research Group","volume":"4","year":"1984","journal-title":"J Am Coll Cardiol"},{"key":"2022101319165094700_euac101-B34","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/0002-8703(86)90269-3","article-title":"Intolerance and ineffectiveness of mexiletine in patients with serious ventricular arrhythmias","volume":"112","author":"Poole","year":"1986","journal-title":"Am Heart J"},{"key":"2022101319165094700_euac101-B35","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0735-1097(87)80276-0","article-title":"Mexiletine: an effective antiarrhythmic drug for treatment of ventricular arrhythmias in congenital heart disease","volume":"10","author":"Moak","year":"1987","journal-title":"J Am Coll Cardiol"},{"key":"2022101319165094700_euac101-B36","doi-asserted-by":"crossref","first-page":"euab116.052","DOI":"10.1093\/europace\/euab116.052","article-title":"Oral procainamide as pharmacological treatment of recurrent and refractory ventricular tachyarrhythmias","volume":"23","author":"Toniolo","year":"2021","journal-title":"Europace"}],"container-title":["EP Europace"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/europace\/article-pdf\/24\/9\/1504\/46500090\/euac101.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/europace\/article-pdf\/24\/9\/1504\/46500090\/euac101.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T19:17:59Z","timestamp":1665688679000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/europace\/article\/24\/9\/1504\/6646054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,19]]},"references-count":36,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,7,19]]},"published-print":{"date-parts":[[2022,10,13]]}},"URL":"https:\/\/doi.org\/10.1093\/europace\/euac101","relation":{},"ISSN":["1099-5129","1532-2092"],"issn-type":[{"value":"1099-5129","type":"print"},{"value":"1532-2092","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,9,1]]},"published":{"date-parts":[[2022,7,19]]}}}